Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) trial

OBJECTIVE: To evaluate open-label adalimumab therapy for clinical effectiveness, fistula healing, patient-reported outcomes and safety in Canadian patients with moderate to severe Crohn’s disease (CD) who were either naive to or previously exposed to antitumour necrosis factor (anti-TNF) therapy. ME...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Panaccione, Remo, Loftus, Edward V, Binion, David, McHugh, Kevin, Alam, Shamsul, Chen, Naijun, Guérette, Benoît, Mulani, Parvez, Chao, Jingdong
التنسيق: Artigo
اللغة:Inglês
منشور في: Pulsus Group Inc 2011
الموضوعات:
Original Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3186726/
https://ncbi.nlm.nih.gov/pubmed/21912766
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة